Investors Buy Large Volume of Precigen Call Options (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) saw some unusual options trading activity on Thursday. Traders acquired 11,343 call options on the stock. This is an increase of 3,908% compared to the typical volume of 283 call options.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Precigen in a report on Friday, November 15th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Precigen presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Iridian Asset Management LLC CT lifted its stake in shares of Precigen by 82.5% in the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after purchasing an additional 1,706,815 shares during the last quarter. Geode Capital Management LLC raised its holdings in Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after buying an additional 149,829 shares during the period. State Street Corp lifted its position in Precigen by 1.0% in the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after buying an additional 29,253 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after buying an additional 127,467 shares during the period. Finally, Renaissance Technologies LLC increased its position in Precigen by 12.4% during the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock valued at $1,869,000 after acquiring an additional 130,500 shares during the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Stock Down 3.6 %

Precigen stock opened at $1.08 on Friday. Precigen has a 52-week low of $0.65 and a 52-week high of $1.93. The firm’s fifty day moving average is $0.84 and its 200 day moving average is $1.09. The company has a market cap of $316.30 million, a price-to-earnings ratio of -1.96 and a beta of 1.71.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.